Unknown

Dataset Information

0

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.


ABSTRACT:

Introduction

Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of venetoclax-based combinations and have begun to address the unmet need in this patient population. As venetoclax-based combinations become increasingly used in the clinical setting, it is important to understand their development, current use, and future directions.

Areas covered

This review covers the clinical development of venetoclax-based combinations for the management of AML, and their current and future use. A search of PubMed and ashpublications.org using the keywords 'venetoclax', 'AML', and 'hypomethylating agents' as the search terms was undertaken to identify the most pertinent publications.

Expert opinion

While venetoclax-based combinations have shown excellent responses and improved survival in patients with untreated AML, further studies are required to understand how to expand on their frontline use, manage patients who fail venetoclax-based combinations, and their true efficacy in the relapsed/refractory setting. Management of AML with venetoclax-based combinations is expected to evolve over the next few years.

SUBMITTER: Othman TA 

PROVIDER: S-EPMC8515853 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.

Othman Tamer A TA   Tenold Matthew E ME   Moskoff Benjamin N BN   Azenkot Tali T   Jonas Brian A BA  

Expert review of hematology 20210501 5


<h4>Introduction</h4>Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of venetoclax-based combinations and have begun to address the unmet need in this patient population. As venetoclax-based combinations become increasingly used in the clinical setting, it is important to understand their development, cur  ...[more]

Similar Datasets

| S-EPMC10067034 | biostudies-literature
| S-EPMC6318429 | biostudies-literature
| S-EPMC11726088 | biostudies-literature
| S-EPMC11868173 | biostudies-literature
| S-EPMC10310786 | biostudies-literature
| S-EPMC6524989 | biostudies-literature
| S-EPMC8237705 | biostudies-literature
| S-EPMC9605800 | biostudies-literature
| S-EPMC5814177 | biostudies-literature